Global biosolutions firm Novonesis is investing €600 million, or about ₹6,600 crore, to build a large enzyme manufacturing plant in Patalganga, India. The facility, expected to be ready by 2030, will serve as a strategic hub for the Middle East, Africa, and South Asia. This expansion follows a strong first half of 2026 for the company, which reported 8% organic sales growth.
Novonesis, the global leader in biosolutions, has announced a significant expansion of its manufacturing footprint with a new facility in Patalganga, India. The company is committing €600 million, equivalent to approximately ₹6,600 crore, to build a high-capacity enzyme production plant. This facility is scheduled to be fully operational by 2030 and will integrate into the company's existing global supply chain network.
Strategic Hub for Emerging Markets
The Patalganga plant is designed to function as a central supply hub for the Middle East, Africa, and South Asia. By centralizing production in India, Novonesis aims to improve operational agility and reduce logistics bottlenecks in these high-growth regions. The company management views these territories as critical for long-term growth, as they are expected to outpace developed markets in demand over the coming decade. Additionally, this investment aligns with the Indian government’s BioE3 policy, which provides incentives to boost domestic bio-industrial infrastructure and capabilities.
Financial Context and Capital Strength
This capital investment comes at a time of robust financial performance for the Danish firm. During the first half of 2026, Novonesis reported 8% organic sales growth, which prompted the company to raise its full-year growth outlook to a range of 7-8%. Profitability remains strong, with the firm expecting its adjusted EBITDA margins to reach the higher end of the 37-38% target range for 2026. The company’s ability to fund such a large project is further supported by a strong cash position; notably, in August 2026, the firm announced its first-ever share buyback program, valued at €1 billion.
Risks and Execution Factors
While the expansion supports long-term growth, it involves inherent execution risks common to large-scale infrastructure projects, such as potential delays in construction or cost overruns. For investors, it is important to note that while the company maintains high profit margins, it remains exposed to currency fluctuations, which can impact reported financial results in its global operations. Furthermore, because growth in core developed markets has been relatively slow, the company is increasingly reliant on successfully penetrating emerging markets to meet its performance targets. Investors will likely monitor future updates regarding project milestones, including environmental clearances, groundbreaking, and construction progress leading up to the 2030 completion date.